Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?

Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells,...

Descripción completa

Detalles Bibliográficos
Autores principales: Maiorano, Brigida Anna, Catalano, Martina, Maiello, Evaristo, Roviello, Giandomenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535083/
https://www.ncbi.nlm.nih.gov/pubmed/37781180
http://dx.doi.org/10.3389/fonc.2023.1254906
_version_ 1785112545780039680
author Maiorano, Brigida Anna
Catalano, Martina
Maiello, Evaristo
Roviello, Giandomenico
author_facet Maiorano, Brigida Anna
Catalano, Martina
Maiello, Evaristo
Roviello, Giandomenico
author_sort Maiorano, Brigida Anna
collection PubMed
description Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells, causing UC cell death. EV has been approved as a single agent for pre-treated mUC, with interesting improvements in response rate and survival in a setting with limited treatment options. More recently, EV approval occurred in cisplatin-ineligible naïve mUC patients in combination with pembrolizumab. Our review aims to summarize the pharmacological properties, clinical studies, and future developments of EV in mUC.
format Online
Article
Text
id pubmed-10535083
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105350832023-09-29 Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually? Maiorano, Brigida Anna Catalano, Martina Maiello, Evaristo Roviello, Giandomenico Front Oncol Oncology Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells, causing UC cell death. EV has been approved as a single agent for pre-treated mUC, with interesting improvements in response rate and survival in a setting with limited treatment options. More recently, EV approval occurred in cisplatin-ineligible naïve mUC patients in combination with pembrolizumab. Our review aims to summarize the pharmacological properties, clinical studies, and future developments of EV in mUC. Frontiers Media S.A. 2023-09-13 /pmc/articles/PMC10535083/ /pubmed/37781180 http://dx.doi.org/10.3389/fonc.2023.1254906 Text en Copyright © 2023 Maiorano, Catalano, Maiello and Roviello https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Maiorano, Brigida Anna
Catalano, Martina
Maiello, Evaristo
Roviello, Giandomenico
Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
title Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
title_full Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
title_fullStr Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
title_full_unstemmed Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
title_short Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
title_sort enfortumab vedotin in metastatic urothelial carcinoma: the solution eventually?
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535083/
https://www.ncbi.nlm.nih.gov/pubmed/37781180
http://dx.doi.org/10.3389/fonc.2023.1254906
work_keys_str_mv AT maioranobrigidaanna enfortumabvedotininmetastaticurothelialcarcinomathesolutioneventually
AT catalanomartina enfortumabvedotininmetastaticurothelialcarcinomathesolutioneventually
AT maielloevaristo enfortumabvedotininmetastaticurothelialcarcinomathesolutioneventually
AT roviellogiandomenico enfortumabvedotininmetastaticurothelialcarcinomathesolutioneventually

Ejemplares similares